Report Description

India vildagliptin market is expected to grow at a steady rate during the forecast period, owing to the increasing diabetic population in the country. Additionally, supportive government policies and improving healthcare infrastructure are also expected to create lucrative opportunities for the market growth over the next few years. Furthermore, initiatives taken by physicians to minimize the costly burden of diabetic complications using combination therapies and novel branded drugs are further expected to rev up the market growth through FY2026.

 

The India vildagliptin market is segmented based on composition, source, strength, distribution channel, application, company and region. Based on source, the market can be split into in-house and contract manufacturing organizations. Out of which, the in-house segment dominated the market until FY2020 owing to in-house production preference by the major market players. The contract manufacturing organizations segment is expected to witness significant growth during the forecast period on account of an upsurge in the number of contract manufacturers in the country and increased outsourcing activities by the major companies in order to focus on their R&D activity and expansion plans. Additionally, contract manufacturing organizations offer competitive pricing and can provide bulk orders in a short duration. This is further projected to contribute to the segmental growth in the coming years.

 

The major players operating in the India vildagliptin market are Abbott India Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Ltd., IPCA Laboratories Ltd., Lupin Limited, Piramal Enterprises Ltd. (Piramal Pharma), Novartis India Limited, Cipla Ltd., Alembic Pharmaceuticals Ltd and others. Major companies are developing advanced technologies, receiving approvals from regulatory bodies and launching new products in order to stay competitive in the market. Other competitive strategies include mergers and acquisitions and new product developments.

Years considered for this report:

Historical Years: FY2016-FY2019

Base Year: FY2020

Estimated Year: FY2021

Forecast Period: FY2022–FY2026

Objective of the Study:

  • To analyze the historical growth in the market size of India vildagliptin market from FY2016 to FY2020.
  • To estimate and forecast the market size of India vildagliptin market from FY2021 to FY2026 and growth rate until FY2026.
  • To classify and forecast India vildagliptin market based on composition, source, strength, distribution channel, application, company and regional distribution.
  • To identify dominant region or segment in the India vildagliptin market.
  • To identify drivers and challenges for the India vildagliptin market.
  • To examine competitive developments such as expansions, new product launches, and mergers & acquisitions in India vildagliptin market.
  • To identify and analyze the profile of leading players operating in the India vildagliptin market.
  • To identify key sustainable strategies adopted by market players in the India vildagliptin market.


Click here to download the sample 

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.


TechSci Research calculated the market size of India vildagliptin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research. 

Key Target Audience:

  • Vildagliptin manufacturers/ suppliers/ distributors
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to vildagliptin

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, India vildagliptin market has been segmented into the following categories, in addition to the industry trends that have also been detailed below:

  • India Vildagliptin Market, By Composition:
    • Monotherapy
    • Combination
  • India Vildagliptin Market, By Source:
    • In-house
    • Contract Manufacturing Organizations
  • India Vildagliptin Market, By Strength:
    • 50 mg
    • 100mg
    • Others
  • India Vildagliptin Market, By Distribution Channel:
    • Online
    • Offline
  • India Vildagliptin Market, By Application:
    • Type 2 Diabetes Mellitus
    • Hyperglycaemia
  • India Vildagliptin Market, By Region:
    • North
    • South
    • East
    • West

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in India vildagliptin market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
India vildagliptin market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.     Product of Interest Introduction: Vildagliptin Market

2.    Research Methodology

3.    Impact of COVID-19 on India Vildagliptin Market

4.    Executive Summary

5.    Voice of Customers/Customer Insights

6.    India Vildagliptin Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value and By Volume

6.2.  Market Share & Forecast

6.2.1.     By Composition (Monotherapy v/s Combination)

6.2.2.     By Source (In-house v/s Contract Manufacturing Organizations)

6.2.3.     By Strength (50 mg, 100mg, Others)

6.2.4.     By Distribution Channel (Online v/s Offline)

6.2.5.     By Application (Type 2 Diabetes Mellitus v/s Hyperglycaemia)

6.2.6.     By Region (North, East, South, West)

6.2.7.     By Company    

6.3.  Product Market Map

7.    North India Vildagliptin Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value and By Volume

7.2.  Market Share & Forecast

7.2.1.     By Composition

7.2.2.     By Source

7.2.3.     By Strength

7.2.4.     By Distribution Channel

7.2.5.     By Application

8.    South India Vildagliptin Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value and By Volume

8.2.  Market Share & Forecast

8.2.1.     By Composition

8.2.2.     By Source

8.2.3.     By Strength

8.2.4.     By Distribution Channel

8.2.5.     By Application

9.    East India Vildagliptin Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value and By Volume

9.2.  Market Share & Forecast

9.2.1.     By Composition

9.2.2.     By Source

9.2.3.     By Strength

9.2.4.     By Distribution Channel

9.2.5.     By Application

10.  West India Vildagliptin Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value and By Volume

10.2.              Market Share & Forecast

10.2.1.  By Composition

10.2.2.  By Source

10.2.3.  By Strength

10.2.4.  By Distribution Channel

10.2.5.  By Application

11.  Market Dynamics

11.1.              Drivers

11.2.              Challenges

12.  Policy & Regulatory Landscape

13.  India Economic Profile

14.  Competitive Landscape

14.1. Company Profiles

14.1.1.  Abbott India Limited

14.1.2.  Torrent Pharmaceuticals Limited

14.1.3.  Intas Pharmaceuticals Limited

14.1.4.  Dr. Reddy’s Laboratories Ltd.

14.1.5.  IPCA Laboratories Ltd.

14.1.6.  Lupin Limited

14.1.7.  Piramal Enterprises Ltd. (Piramal Pharma)

14.1.8.  Novartis India Limited

14.1.9.  Cipla Ltd.

14.1.10. Alembic Pharmaceuticals Ltd.

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

down-arrow

down-arrow

down-arrow